Question for written answer E-004361/2021

to the Commission

Rule 138

Krzysztof Hetman (PPE)

Subject: Ensuring continuity of vaccine supply

The decision to negotiate jointly with pharmaceutical companies and buy COVID-19 vaccines on a joint basis was a good one, but it has not avoided supply problems. Some vaccine manufacturers have not stuck by their commitments, often cancelling deliveries from one day to the next. This has caused huge difficulties for Member States in organising their vaccination programmes and for the possibility of administering second doses on time, thereby making it more difficult to keep to the vaccination schedule.

In light of the above:

1. Were there any clauses contained in the vaccine purchase contracts concerning late supply or a sudden interruption in supplies? Have there been any consequences for vaccine manufacturers failing to comply with the contract, and if so which manufacturers were concerned?

2. Has there been an analysis of the vaccine purchasing process so far, including any problems in supplies and the contractual arrangements in the existing contracts, with a view to eliminating similar difficulties and ensuring continuity of vaccine supply in the future?

3. How does the Commission intend to tackle future delays or interruptions?